Mild heating of amphotericin B-desoxycholate: Effects on ultrastructure, in vitro activity and toxicity, and therapeutic efficacy in severe candidiasis in leukopenic mice

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 6, 2000, Pages 1598-1603

  Van Etten, Els W M ^a   Van Vianen, Wim ^a   Roovers, Patty ^a   Frederik, Peter ^b  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; DRUG EFFICACY; DRUG FORMULATION; DRUG TOLERABILITY; FEMALE; HEATING; HEMOLYSIS; LEUKOPENIA; MOUSE; NONHUMAN; PRIORITY JOURNAL;

AMPHOTERICIN B; ANIMALS; ANTIBIOTICS, ANTIFUNGAL; CANDIDIASIS; CHEMISTRY, PHARMACEUTICAL; LEUKOPENIA; MICE; TEMPERATURE;

EID: 0034036413     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.6.1598-1603.2000     Document Type: Article

References (14)

1. Gaboriau, F., M. Chéron, L. Leroy, and J. Bolard. 1997. Physicochemical properties of the heat induced 'super' aggregates of amphotericin B. Biophys. Chem. 66:1-12.
2. Gaboriau, F., M. Chéron, C. Petit, and J. Bolard. 1997. Heat-induced superaggregation of amphotericin B reduces its in vitro toxicity: a new way to improve its therapeutic index. Antimicrob. Agents Chemother. 41:2345-2351.
3. Hiemenz, J. W., and T. J. Walsh. 1996. Lipid formulations of amphotericin B: recent progress and future directions. Clin. Infect. Dis. 22(Suppl. 2):S133-S144.
4. Juliano, R. L., C. W. M. Grant, K. R. Barber, and M. A. Kalp. 1987. Mechanism of the selective toxicity of amphotericin B incorporated into liposomes. Mol. Pharmacol. 31:1-11.
5. Leenders, A. C., and S. de Marie. 1996. The use of lipid formulations of amphotericin B for systemic fungal infections. Leukemia 10:1570-1575.
6. Leenders, A. C., S. de Marie, M. T. ten Kate, I. A. Bakker-Woudenberg, and H. A. Verbrugh. 1996. Liposomal amphotericin B (AmBisome) reduces dissemination of infection as compared to amphotericin B deoxycholate (Fungizone) in a rat model of pulmonary aspergillosis. J. Antimicrob. Chemother. 38:215-225.
7. Mehta, R., G. Lopez-Berestein, R. Hopfer, K. Mills, and R. L. Juliano. 1984. Liposomal amphotericin B is toxic to fungal cells but not to mammalian cells. Biochim. Biophys. Acta 770:230-234.
8. Petit, C., M. Chéron, V. Joly, J. M. Rodrigues, J. Bolard, and F. Gaboriau. 1998. In vivo therapeutic efficacy in experimental murine mycoses of a new formulation of desoxycholate-amphotericin B obtained by mild heating. J. Antimicrob. Chemother. 42:779-785.
9. Petit, C., V. Yardley, F. Gaboriau, J. Bolard, and S. L. Croft. 1999. Activity of a heat-induced reformulation of amphotericin B deoxycholate (Fungizone) against Leishmania donovani. Antimicrob. Agents Chemother. 43:390-392.
10. Robinson, R. F., and M. C. Nahata. 1999. A comparative review of conventional and lipid formulations of amphotericin B. J. Clin. Pharm. Ther. 24: 249-257.
11. Van Etten, E. W. M., C. van den Heuvel-de Groot, and I. A. J. M. Bakker-Woudenberg. 1993. Efficacies of amphotericin B-desoxycholate (Fungizone), liposomal amphotericin B (AmBisome) and fluconazole in the treatment of systemic candidosis in immunocompetent and leucopenic mice. J. Antimicrob. Chemother. 32:723-739.
12. Van Etten, E. W. M., M. T. ten Kate, L. E. T. Stearne, and I. A. J. M. Bakker-Woudenberg. 1995. Amphotericin B liposomes with prolonged circulation in blood: in vitro antifungal activity, toxicity, and efficacy in systemic candidiasis in leukopenic mice. Antimicrob. Agents Chemother. 39:1954-1958.
13. Van Etten, E. W. M., M. T. ten Kate, S. V. Snijders, and I. A. J. M. Bakker-Woudenberg. 1998. Administration of liposomal agents and blood clearance capacity of the mononuclear phagocyte system. Antimicrob. Agents Chemother. 42:1677-1681.
14. Wasan, K. M., and S. M. Cassidy. 1998. Role of plasma lipoproteins in modifying the biological activity of hydrophobic drugs. J. Pharm. Sci. 87:411-424.